Microbiologists receive top Canadian RecognitionOne is a veteran researcher.

Miguel Valvano, Professor and Chairman, Department of Microbiology and Immunology at the Schulich School of Medicine & Dentistry received the prestigious CSM / Roche Diagnostics Award for outstanding achievements and Dr. John McCormick, an assistant professor in the Department of Microbiology received the Fisher Scientific Award for New researchers in microbiological sciences.. Microbiologists receive top Canadian RecognitionOne is a veteran researcher, the other new , but two microbiologists from the University of Western Ontario have been both to isolated national recognition for her work on infectious diseases and immunity from the receiving Canadian Society of microbiologists .

Dattoli of local doctor wrote, revisedProstate Brachytherapy Made Complicated by Michael Dattoli, MD, co-author, Kent Wallner, MD, Gregory Merrrick, and John Blasko, MD – arguably the tip of the medical textbook and a comprehensive reference on the subject of prostate seed implantation, a third time has been revised. Dattoli is physician-in-chief. Sarasota at Dattoli Cancer Center & Brachytherapy Research Institute – Published by the Smart Medicine Press, Seattle, Washington , the new volume is released 21st January 2008. It was first published in 1998, the second edition coming in 2001.Cause acute need for new therapies options for these patients.. About Acute myeloic leukemiaAML is a rapidly advancing cancer of the blood through the uncontrolled reproduction of unripe blast cells in the bone marrow. The National Cancer Institute has estimated that nearly 13,000 new cases are by AML was diagnosed and approximately 9,000 deaths due to AML entered in the U.S. In 2009. Further it is estimated that prevalence 25,000 in the U.S. AML AML is basically a condition of the elderly adult and the average age of a patient with AML diagnose approximately 67 years.

Belief, such as we value as best to financed of our voreloxin development the program, including our planned Phase 3 trial, we are still talks with potential pharmaceutical partners. .. Sunesis announced today that as part of the global development strategy, DNA damage that -submission meeting for the current quarter with a with the European Medicines Agency EMA receive research advice for the development to voreloxin, including the actions proposed Phase 3 clinical trial. We are pleased pleased with the results of this milestone meeting with the FDA and are pleased to initiating of our multinational Phase 3 clinical trial, stated Daniel Swisher, Chief Executive Officer of Sunesis.